Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
The migration of venture capital from biopharma companies stepped up during the first three months of 2012, despite recent signs of life in the IPO market. The dollar value of VC deals fell 18% during the first quarter, while the number of deals was relatively flat. Just $780 million was invested in a total 99 biopharma companies during Q1 ’12, compared with $949 million in 97 deals during the first quarter of 2011. The report also showed a sharp year-over-year drop in first-sequence investment activity, as biopharma investors seek safer bets on established companies. There were 10 Series A deals totaling $93.2 million in Q1’12 compared to $134.3 million in 30 deals during last year’s first quarter. What are your predictions for Q2 2012?